1-20 of 497 results for subject:"Viral diseases"
Librarians' tools
- Search time
- 0.306 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:"Viral diseases"
- We searched for
- subject_t:"Viral diseases" OR subject_t:Viruses OR subject_ses:93427
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps he is taking to help support diagnostic testing of fevers in countries in Sub-Saharan Africa.
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps he is taking to help support diagnostic testing of fevers in countries in Sub-Saharan Africa.
The UK Government through the Foreign, Commonwealth and Development Office is a long-term supporter of Product Development Partnerships to develop novel health technologies for diseases where commercial markets fail. This support has led to the development of diagnostics for sleeping sickness, malaria, tuberculosis and COVID-19. Additionally, the UK's current £1 billion pledge to the Global Fund supports testing, treatment, and prevention initiatives across Sub-Saharan Africa and strengthens health systems, helping countries prevent, prepare for, and respond to pandemics. Programmes supported by the Global Fund performed 335 million malaria tests in 2023. Through our £1.65 billion investment in Gavi, the vaccine alliance from 2021-25, the UK is supporting the vaccination of 300 million children, and the procurement and distribution of yellow fever and cholera diagnostic tests. Finally, our £95 million Tackling Deadly Diseases in Africa programme (TDDAP) is strengthening national public health surveillance and laboratory systems to better detect and respond to public health threats and outbreaks in Ghana, Kenya, Malawi, Uganda and DRC.
To ask the Secretary of State for Health and Social Care, whether his Department plans to expand the emergency department bloodborne virus opt-out testing programme to (a) King’s Mill Hospital, (b) Lincoln County Hospital, (c) Pilgrim Hospital and (d) other sites in the East Midlands.
To ask the Secretary of State for Health and Social Care, whether his Department plans to expand the emergency department bloodborne virus opt-out testing programme to (a) King’s Mill Hospital, (b) Lincoln County Hospital, (c) Pilgrim Hospital and (d) other sites in the East Midlands.
The Emergency Department opt-out testing programme will continue to test individuals for bloodborne viruses, including HIV and viral hepatitis, in line with committed funding plans.
None of the funding already committed has been removed from sites offering opt-out testing for viral hepatitis. NHS England is currently reviewing its budgetary position, with a view to determining whether funding can be made available to extend the provision of opt-out testing for viral hepatitis. In particular, NHS England is reviewing this for sites whose committed funding will end during 2025.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a centre of excellence for the (a) care and (b) research of (i) post-viral and (ii) infection-associated conditions.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a centre of excellence for the (a) care and (b) research of (i) post-viral and (ii) infection-associated conditions.
We do not anticipate setting up a new centre of excellence for care and research specifically for post-viral or infection-associated conditions. The Department funds research on post-viral conditions through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral and infection-associated conditions such as myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID, and are actively exploring next steps for stimulating further research in this area. The MRC and NIHR currently fund research through a variety of routes, including infrastructure, research programmes, capacity building, for example with research fellowships, and in the case of the NIHR, research delivery to support recruitment to studies. Funding is available for post-viral and infection-associated research.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 February 2025 to Question 25535 on Viral Diseases, if he will make an assessment of the potential impact of means-testing the winter fuel payment on the number of cases of (a) flu, (b)...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 February 2025 to Question 25535 on Viral Diseases, if he will make an assessment of the potential impact of means-testing the winter fuel payment on the number of cases of (a) flu, (b)...
The Department has no current plans to undertake an assessment of the potential impact of means-testing the winter fuel payment on the number of flu, COVID-19, norovirus and respiratory syncytial virus cases.
The relationship between cold weather and respiratory illness in general, such as exacerbation of chronic bronchitis, is well established in scientific evidence. However, a link from cold snaps, or housing temperature, to respiratory infections does not have the same evidential base.
Further information is available at the following link:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 January 2025 to Question 24011 on Coronavirus: Disease Control, when he plans to update the National Infection Prevention and Control Manual and Health Technical Memoranda guidelines to ensure (a) recognition of the role...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 January 2025 to Question 24011 on Coronavirus: Disease Control, when he plans to update the National Infection Prevention and Control Manual and Health Technical Memoranda guidelines to ensure (a) recognition of the role...
The NHS England National Infection Prevention and Control Manual (NIPCM) provides adaptable guidance to support local decision-making. Healthcare organisations are responsible for conducting dynamic risk assessments to determine when enhanced infection control measures, such as the use of FFP3 masks, are necessary. These assessments take into account factors such as ventilation quality, local infection prevalence and specific care environments.
Should new evidence emerge that warrants updates, the guidance will be reviewed and revised accordingly by NHS England and UKHSA to ensure the highest standards of infection prevention and control are maintained across healthcare settings. Any updates will be disseminated appropriately to healthcare employers and providers to support consistent implementation
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of means-testing the winter fuel payment on the number of (a) flu, (b) Covid, (c) norovirus and (d) RSV cases.
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of means-testing the winter fuel payment on the number of (a) flu, (b) Covid, (c) norovirus and (d) RSV cases.
An assessment of the potential impact of means-testing the winter fuel payment on the number of flu, COVID-19, norovirus, and respiratory syncytial virus cases has not been produced. The Government has taken action to ensure low-income households are protected this winter.
To ask the Secretary of State for Health and Social Care, what steps he is taking to stop the spread of the HMPV virus from China.
To ask the Secretary of State for Health and Social Care, what steps he is taking to stop the spread of the HMPV virus from China.
Human metapneumovirus (hMPV) is one of many viruses within the United Kingdom that cause illness each winter. It has been in circulation for many decades. Most people have been infected by the age of five and reinfection occurs throughout life.
The UK Health and Security Agency (UKHSA) monitors activity and publishes data every week through the winter period. UKHSA’s long-term surveillance of hMPV in England, through systems covering general practice surgeries and hospital laboratories, indicates that hMPV levels in winter 2024-25 are in line with what we would expect to see at this time of year.
UKHSA has issued general public advice on prevention of transmission of respiratory viruses, this includes the importance of good hand hygiene, catching coughs with tissues, and avoiding vulnerable people while symptomatic. These measures would be expected to reduce transmission of hMPV.
To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) his international counterparts and (b) the World Health Organisation on human metapneumovirus.
To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) his international counterparts and (b) the World Health Organisation on human metapneumovirus.
The UK Health Security Agency (UKHSA) has had no recent communications from the World Health Organisation or other countries in relation to human metapneumovirus (hMPV).
UKHSA’s long-term surveillance of hMPV in England, through systems covering general practice surgeries and hospital laboratories, indicates that hMPV levels in winter 2024-25 are in line with what we would expect to see at this time of year.
Healthcare data for hMPV and other respiratory viruses is routinely published on the UKHSA dashboard, which is available at the following link:
https://ukhsa-dashboard.data.gov.uk/respiratory-viruses/other-respiratory-viruses
To ask the Secretary of State for Health and Social Care, how many cases of human metapneumovirus have been identified in the UK.
To ask the Secretary of State for Health and Social Care, how many cases of human metapneumovirus have been identified in the UK.
The UK Health Security Agency’s long-term surveillance of human metapneumovirus (hMPV) in England, through systems covering general practice surgeries and hospital laboratories, indicates that hMPV levels in winter 2024-25 are in line with what we would expect to see at this time of year.
Healthcare data for hMPV and other respiratory viruses comes from the sentinel surveillance system, a data collection method used to monitor trends. This means it is not a count of every person being treated for the respiratory virus in hospital. Total case numbers are therefore not held centrally.
Further information on data collection is available at the following link:
To ask the Secretary of State for Health and Social Care, whether his Department plans to continue funding for the opt-out blood-borne virus testing programme at (a) St George's, Epsom and (b) St Helier Hospitals and Health Group beyond March 2025.
To ask the Secretary of State for Health and Social Care, whether his Department plans to continue funding for the opt-out blood-borne virus testing programme at (a) St George's, Epsom and (b) St Helier Hospitals and Health Group beyond March 2025.
On 28 November 2024, the Prime Minister announced a further £27 million of funding for the continuation of the HIV Emergency Department opt-out testing programme for 2025/26. As part of the extension, more than 90 sites will be offered funding to continue or begin the roll out of HIV opt out testing until March 2026, including St George's, Epsom, and St Helier hospitals.
NHS England will evaluate the costs and feasibility of further extending this programme regarding hepatitis B and C opt-out testing, once budgets for 2025/26 are confirmed, and expects to provide an update on their decision in the early new year.
There are currently no plans to extend opt-out HIV testing beyond emergency departments. However, the Department, together with the UK Health and Security Agency, and NHS England are working together in the development of a new HIV Action Plan, which will include a focus on scaling up HIV testing, and which we aim to publish in summer 2025.
To ask His Majesty’s Government what steps they are taking to reduce the impact of a potential “quad-demic”, involving high prevalence of influenza, respiratory syncytial virus, COVID-19 and norovirus, following the warning of Professor Sir Stephen Powis, the NHS national medical director.
To ask His Majesty’s Government what steps they are taking to reduce the impact of a potential “quad-demic”, involving high prevalence of influenza, respiratory syncytial virus, COVID-19 and norovirus, following the warning of Professor Sir Stephen Powis, the NHS national medical director.
My Lords, levels of hospital admissions due to flu and norovirus are higher, while Covid hospitalisation rates are lower and RSV hospitalisation rates are about the same as the same time last year. The impact of these infectious diseases can be reduced through our annual vaccination programmes for flu and Covid-19, as well as the new year-round vaccination programme for RSV, and by observing good hygiene measures. Some 16.6 million flu vaccinations, 9.3 million Covid-19 vaccinations and 1.2 million RSV vaccinations have been delivered so far this winter.
My Lords, levels of hospital admissions due to flu and norovirus are higher, while Covid hospitalisation rates are lower and RSV hospitalisation rates are about the same as the same time last year. The impact of these infectious diseases can be reduced through our annual vaccination programmes for flu and Covid-19, as well as the new year-round vaccination programme for RSV, and by observing good hygiene measures. Some 16.6 million flu vaccinations, 9.3 million Covid-19 vaccinations and 1.2 million RSV vaccinations have been delivered so far this winter.
My Lords, levels of hospital admissions due to flu and norovirus are higher, while Covid hospitalisation rates are lower and RSV hospitalisation rates are about the same as the same time last year. The impact of these infectious diseases can be reduced through our annual vaccination programmes for flu and Covid-19, as well as the new year-round vaccination programme for RSV, and by observing good hygiene measures. Some 16.6 million flu vaccinations, 9.3 million Covid-19 vaccinations and 1.2 million RSV vaccinations have been delivered so far this winter.
To ask His Majesty’s Government what steps they are taking to reduce the impact of a potential “quad-demic”, involving high prevalence of influenza, respiratory syncytial virus, COVID-19 and norovirus, following the warning of Professor Sir Stephen Powis, the NHS national medical director.
My Lords, I thank my noble friend the Minister for that comprehensive Answer. I have to say that “quad-demic” was a new phrase for me and so I was very keen to understand what the Minister made of the announcements from the NHS national medical director, Sir Stephen Powis. From my point of view, it is vital that we learn
the lessons of the last pandemic and I know a huge amount of work is being done to understand the implications of the recommendations from Module 1 of the inquiry. But, as I understand it from Sir Stephen’s announcement, the uptake of NHS vaccine programmes is much lower than last year, so I am concerned for us to be reassured that if uptake does not improve in the run-up to Christmas, we are ready and we have learned the lessons from last time and we will not panic and start making foolish decisions about PPE acquisition, for example.
My Lords, I thank my noble friend the Minister for that comprehensive Answer. I have to say that “quad-demic” was a new phrase for me and so I was very keen to understand what the Minister made of the announcements from the NHS national medical director, Sir Stephen Powis. From my point of view, it is vital that we learn
the lessons of the last pandemic and I know a huge amount of work is being done to understand the implications of the recommendations from Module 1 of the inquiry. But, as I understand it from Sir Stephen’s announcement, the uptake of NHS vaccine programmes is much lower than last year, so I am concerned for us to be reassured that if uptake does not improve in the run-up to Christmas, we are ready and we have learned the lessons from last time and we will not panic and start making foolish decisions about PPE acquisition, for example.
We are absolutely committed to learning the lessons from Covid in order to build resilience. The recommendations of the independent review of procurement by Nigel Boardman have already been implemented and a Covid Counter-Fraud Commissioner has already been appointed to scrutinise contracts to learn the lessons and recover money for taxpayers. Professor Sir Stephen Powis, who I have spoken to about this, was not suggesting that there is a pandemic but more that four infectious diseases are coalescing to create a situation and that vaccination is crucial. His comments were a call to the public to get vaccinated, which I also endorse.
We are absolutely committed to learning the lessons from Covid in order to build resilience. The recommendations of the independent review of procurement by Nigel Boardman have already been implemented and a Covid Counter-Fraud Commissioner has already been appointed to scrutinise contracts to learn the lessons and recover money for taxpayers. Professor Sir Stephen Powis, who I have spoken to about this, was not suggesting that there is a pandemic but more that four infectious diseases are coalescing to create a situation and that vaccination is crucial. His comments were a call to the public to get vaccinated, which I also endorse.
We are absolutely committed to learning the lessons from Covid in order to build resilience. The recommendations of the independent review of procurement by Nigel Boardman have already been implemented and a Covid Counter-Fraud Commissioner has already been appointed to scrutinise contracts to learn the lessons and recover money for taxpayers. Professor Sir Stephen Powis, who I have spoken to about this, was not suggesting that there is a pandemic but more that four infectious diseases are coalescing to create a situation and that vaccination is crucial. His comments were a call to the public to get vaccinated, which I also endorse.
My Lords, I thank my noble friend the Minister for that comprehensive Answer. I have to say that “quad-demic” was a new phrase for me and so I was very keen to understand what the Minister made of the announcements from the NHS national medical director, Sir Stephen Powis. From my point of view, it is vital that we learn
the lessons of the last pandemic and I know a huge amount of work is being done to understand the implications of the recommendations from Module 1 of the inquiry. But, as I understand it from Sir Stephen’s announcement, the uptake of NHS vaccine programmes is much lower than last year, so I am concerned for us to be reassured that if uptake does not improve in the run-up to Christmas, we are ready and we have learned the lessons from last time and we will not panic and start making foolish decisions about PPE acquisition, for example.
My Lords, currently the RSV vaccination is available to the older age group of 75 to 79 year-olds—of course, it is available to a younger age group for vulnerable people—unlike in the CDC advice, which is that over-75s should get the immunisation. Older people are more susceptible to RSV and end up with more severe disease and hospitalisation, so why is the advice in the United Kingdom that the over-80s should not get immunisation? It has been suggested that the trials had insufficient evidence. The two trials for Moderna and Pfizer showed that efficacy was maintained in the older age group and therefore the JCVI’s interpretation is rather narrow in scientific terms —or is it to save money?
My Lords, currently the RSV vaccination is available to the older age group of 75 to 79 year-olds—of course, it is available to a younger age group for vulnerable people—unlike in the CDC advice, which is that over-75s should get the immunisation. Older people are more susceptible to RSV and end up with more severe disease and hospitalisation, so why is the advice in the United Kingdom that the over-80s should not get immunisation? It has been suggested that the trials had insufficient evidence. The two trials for Moderna and Pfizer showed that efficacy was maintained in the older age group and therefore the JCVI’s interpretation is rather narrow in scientific terms —or is it to save money?
I listened carefully to the noble Lord. The JCVI considered that there was less certainty about how well the RSV vaccine works in people aged 80 and over when the programme was introduced in 2023, and that is because, as the noble Lord said, there were insufficient people aged 80 and older in the clinical trials. The JCVI continues to keep this under review, including looking at data from clinical trials and evidence in other countries, and there will shortly be an update to your Lordships’ House in respect of research and clinical trials.
I listened carefully to the noble Lord. The JCVI considered that there was less certainty about how well the RSV vaccine works in people aged 80 and over when the programme was introduced in 2023, and that is because, as the noble Lord said, there were insufficient people aged 80 and older in the clinical trials. The JCVI continues to keep this under review, including looking at data from clinical trials and evidence in other countries, and there will shortly be an update to your Lordships’ House in respect of research and clinical trials.
I listened carefully to the noble Lord. The JCVI considered that there was less certainty about how well the RSV vaccine works in people aged 80 and over when the programme was introduced in 2023, and that is because, as the noble Lord said, there were insufficient people aged 80 and older in the clinical trials. The JCVI continues to keep this under review, including looking at data from clinical trials and evidence in other countries, and there will shortly be an update to your Lordships’ House in respect of research and clinical trials.
My Lords, currently the RSV vaccination is available to the older age group of 75 to 79 year-olds—of course, it is available to a younger age group for vulnerable people—unlike in the CDC advice, which is that over-75s should get the immunisation. Older people are more susceptible to RSV and end up with more severe disease and hospitalisation, so why is the advice in the United Kingdom that the over-80s should not get immunisation? It has been suggested that the trials had insufficient evidence. The two trials for Moderna and Pfizer showed that efficacy was maintained in the older age group and therefore the JCVI’s interpretation is rather narrow in scientific terms —or is it to save money?
The Minister says that we are determined to learn the lessons of Covid. During Covid we had vaccination rates of 90% but, as she said, only 16 million—just 25%—of our citizens have had the flu jab and vaccination rates among children are also deteriorating at a rate. I say this with some personal interest because there was an outbreak of the quad-demic in my own household at 2 am today. There are three times as many people in hospital today with flu than in this week last year. Can the Minister please explain what she is doing to increase vaccination rates, particularly among children?
The Minister says that we are determined to learn the lessons of Covid. During Covid we had vaccination rates of 90% but, as she said, only 16 million—just 25%—of our citizens have had the flu jab and vaccination rates among children are also deteriorating at a rate. I say this with some personal interest because there was an outbreak of the quad-demic in my own household at 2 am today. There are three times as many people in hospital today with flu than in this week last year. Can the Minister please explain what she is doing to increase vaccination rates, particularly among children?
We are aiming communications —I know the noble Lord will be familiar with this from his previous role—particularly at groups that are less represented in terms of vaccinations. From my discussions with the national medical director, I do not recognise the reference that the noble Lord made to hospitalisations; they are as I set out in the Answer to my noble friend. However, we are far from complacent and continue to push vaccination. We will get vaccination rates up because they are the best line of defence against infectious diseases.
We are aiming communications —I know the noble Lord will be familiar with this from his previous role—particularly at groups that are less represented in terms of vaccinations. From my discussions with the national medical director, I do not recognise the reference that the noble Lord made to hospitalisations; they are as I set out in the Answer to my noble friend. However, we are far from complacent and continue to push vaccination. We will get vaccination rates up because they are the best line of defence against infectious diseases.
We are aiming communications —I know the noble Lord will be familiar with this from his previous role—particularly at groups that are less represented in terms of vaccinations. From my discussions with the national medical director, I do not recognise the reference that the noble Lord made to hospitalisations; they are as I set out in the Answer to my noble friend. However, we are far from complacent and continue to push vaccination. We will get vaccination rates up because they are the best line of defence against infectious diseases.
The Minister says that we are determined to learn the lessons of Covid. During Covid we had vaccination rates of 90% but, as she said, only 16 million—just 25%—of our citizens have had the flu jab and vaccination rates among children are also deteriorating at a rate. I say this with some personal interest because there was an outbreak of the quad-demic in my own household at 2 am today. There are three times as many people in hospital today with flu than in this week last year. Can the Minister please explain what she is doing to increase vaccination rates, particularly among children?
My Lords, the chief medical officer at the UK Health Security Agency stated last week that NHS staff should get the flu vaccination. The Government’s own statistics show that last week, in the largest trust in the country, only 7.9% of those eligible had had flu jabs, and on average the number is in the lower 20%. Why has this happened? What are the Government doing urgently to improve the take-up of the flu vaccine by NHS staff?
My Lords, the chief medical officer at the UK Health Security Agency stated last week that NHS staff should get the flu vaccination. The Government’s own statistics show that last week, in the largest trust in the country, only 7.9% of those eligible had had flu jabs, and on average the number is in the lower 20%. Why has this happened? What are the Government doing urgently to improve the take-up of the flu vaccine by NHS staff?
I must be honest: I cannot explain here the exact reasons why NHS staff are not taking it up, but I assure the noble Lord, as I have assured other noble Lords, that our focus is on getting vaccination rates up. That is why the national medical director made the comments that he did, as well as assuring me that we are not nearing a pandemic.
I must be honest: I cannot explain here the exact reasons why NHS staff are not taking it up, but I assure the noble Lord, as I have assured other noble Lords, that our focus is on getting vaccination rates up. That is why the national medical director made the comments that he did, as well as assuring me that we are not nearing a pandemic.
I must be honest: I cannot explain here the exact reasons why NHS staff are not taking it up, but I assure the noble Lord, as I have assured other noble Lords, that our focus is on getting vaccination rates up. That is why the national medical director made the comments that he did, as well as assuring me that we are not nearing a pandemic.
My Lords, the chief medical officer at the UK Health Security Agency stated last week that NHS staff should get the flu vaccination. The Government’s own statistics show that last week, in the largest trust in the country, only 7.9% of those eligible had had flu jabs, and on average the number is in the lower 20%. Why has this happened? What are the Government doing urgently to improve the take-up of the flu vaccine by NHS staff?